[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100335289":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":44,"collaborators":20,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":20,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":20,"maxAge":20,"enrollmentInfo":54,"targetDuration":20,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Shenzhen Geno-Immune Medical Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Lentiviral TYF-CGD-modified autologous stem cells","EXPERIMENTAL","Autologous hematopoietic stem cells transduced with lentiviral TYF vector carrying the functional gene",[13],"Genetic: Infusion of lentiviral TYF-CGD-modified autologous stem cells",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"GENETIC","Infusion of lentiviral TYF-CGD-modified autologous stem cells","Infusion of lentiviral TYF-modified autologous stem cells at 1\\~10x10\\^6 gene-modified cells per kg body weight",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Lung-Ji Chang, Ph.D","CONTACT","+86 0755-86573763","c@szgimi.org",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Shenzhen Geno-immune Medical Institute","RECRUITING","Shenzhen","Guangdong","518000","China","CN",{"type":37,"coordinates":38},"Point",[39,40],114.0683,22.54554,{"lat":40,"lon":39},[43],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":45,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100335289","lentiviral-gene-therapy-for-cgd-100335289",false,"NCT03645486","Lentiviral Gene Therapy for CGD","Lentiviral Gene Therapy for Chronic Granulomatous Disease (CGD)","Inclusion Criteria:\n\n1. CGD patients \\>= 0 years of age\n2. Molecular diagnosis confirmed by DNA sequencing and supported by laboratory evidence for absent or significantly reduced biochemical activities of the NADPH-oxidase\n3. Karnofsky-Index \\> =70%\n4. At least one prior, ongoing or refractory severe infection and\u002For inflammatory complications requiring hospitalization despite drug intervention\n5. Written informed consent for adult patient, and assent for pediatric subjects seven years or older\n\nExclusion Criteria:\n\n1. Contraindication for leukapheresis (anaemia Hb \\\u003C8g\u002Fdl, cardiovascular instability, severe coagulopathy) or for administration of conditioning medication\n2. Female patients who are pregnant or lactating as determined by history and\u002For positive pregnancy test","ALL",{"count":55,"type":56},10,"ESTIMATED","INTERVENTIONAL",[59],"NA","This is a Phase I\u002FII clinical trial of gene therapy for treating Chronic Granulomatous Disease using a high-safety, high-efficiency, self-inactivating lentiviral vector TYF to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the TYF-CGD gene transfer clinical protocol.",[62],"Chronic Granulomatous Disease",[64,65],"Chronic granulomatous disease","Lentiviral vector","2026-06-18",{"date":68,"type":69},"2026-06-22","ACTUAL",{"date":71,"type":69},"2025-07-01",{"date":73,"type":56},"2029-12-31",{"name":5,"class":6},1]